Edward Kim, M.D., Ph.D.
- Assistant Professor of Medicine
- Chair, UC Davis Pancreatic Cancer Research Incubator
- Chair, Data and Safety Monitoring Committee, UC Davis Comprehensive Cancer Center
Dr. Kim is an adult medical oncologist who specializes in medical treatment of gastrointestinal malignancies including pancreatic, hepatocellular, biliary, esophageal, gastric, and colorectal cancers.
He has expertise in conducting clinical trials for these malignancies and has a particular interest in novel treatments for pancreatic cancer.
For Gastrointestinal Oncology Clinical Trials at UC Davis Comprehensive Cancer Center, click here.
Dr. Kim’s research includes developing and conducting clinical trials for gastrointestinal malignancies. He has a particular interest in translational and clinical research for pancreatic cancer.
His laboratory research is focused in 2 primary areas: 1) investigation and development of novel rational combinations of drugs for pancreatic cancer, and 2) development of patient-derived models of pancreatic cancer (including patient-derived xenografts and patient-derived organoids) to enhance pre-clinical evaluation of promising new therapeutics for pancreatic cancer.
Hematology and Oncology
M.D., Stony Brook University, Stony Brook NY 2005
Ph.D., Stony Brook University, Stony Brook NY 2003
A.B., Harvard University, Cambridge MA 1997
Internal Medicine, University of Michigan , Ann Arbor MI 2005-2007
Hematology/Oncology, University of Michigan , Ann Arbor MI 2007-2011
American Board of Internal Medicine, 2008
American Board of Internal Medicine, Medical Oncology, 2012
American Association for Canter Research (AACR)
American Society of Clinical Oncology (ASCO)
Southwest Oncology Group (SWOG)
Honors and Awards
NCI Cancer Clinical Team Leadership Award, 2015
ASCO Cancer Foundation Merit Award – GI Cancers Symposium, 2011
Mark Roth Memorial Award, 2010
Select Recent Publications
To view a detailed list of Dr. Kim's publications, please click here.
Semrad, T.J., Kim, E.J., Tanaka, M., Sands, J., Roberts, C., Burich, R.A., Gandara, D.R., Lara, P., Mack, P.C. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treatment and Research Communications. 2017, 10; 21-26.
Zhen, D.B., Griffith, K.A., Ruch, J.M., Camphausen, K., Savage, J.E., Kim, E.J., Sahai, V., Simeone, D.M., Zalupski, M.M. A Phase I Trial of Cabozantinib and Gemcitabine in Advanced Pancreatic Cancer. Investigational New Drugs. 2016 Dec;34(6):733-739.
Tu, M., Pan, Y., Qiu, J., Kim, E.J., Yu, A. MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Oncotarget. 2016 Jul 19;7(29):45547-45561.
Davis, E.J., Griffith, K.A., Kim, E.J., Ruch, J.M., McDonnell, K.J., Zalupski, M.M. A phase II study of biweekly cisplatin, fixed dose rate gemcitabine and infusional 5-fluorouracil in patients with metastatic pancreatic and biliary cancers. Am J Clin Oncol. 2015 Nov 3.[Epub ahead of print].
Kim, E.J., Semrad, T.J., Bold, R.J. Phase II clinical trials on Investigational drugs for the Treatment of Pancreatic Cancers. Expert Opin Investig Drugs. 2015 Jun;24(6):781-94.
Semrad, T., Barzi, A., Lenz, H-J., Hutchins, I.M., Kim, E.J., Gong, I-Y., Tanaka, M., Beckett, L., Holland, W., Burich, R.A., Synder-Solis, L., Mack, P., Lara Jr., P. Pharmacodynamic Separation of Gemcitabine and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer: Therapeutic and Biomarker Results. Int J Clin Oncol. 2015 Jun;20(3):518-24.
Kim, E.J., Sahai, V., Abel, E.V., Griffith, K.A., Greenson, J.K., Takebe, N., Khan, G.N., Blau, J.L., Balis, U.G., Craig, R., Zalupski, M.M., Simeone, D.M. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23):5937-45.
Abel, E.V., Kim, E.J., Wu, J., Hynes, M., Bednar, F., Proctor, E., Wang, L., Dziubinski, M.L., Simeone, D.M. The notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS One. 2014 Mar 19;9(3):e91983.
Kim, E.J., Ben-Josef, E., Herman, J.M., Bekaii-Saab, T., Dawson, L.A., Griffith, K.A., Francis, I.R., Greenson, J.K., Simeone, D.M., Lawrence, T.S., Laheru, D., Wolfgang, C.L., Williams, T., Bloomston, M., Moore, M.J., Wei, A., Zalupski, M.M. A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer. Cancer. 2013 Aug 1;119(15):2692-700.
Yen, W., Fischer, M.F., Hynes, M., Wu, J.J., Kim, E., Beviglia, L., Yeung, V.P., Song, X., Kapoun, A.M., Lewicki, J., Gurney, A., Simeone, D.M., Hoey, T. Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells. Clin Canc Res. 2012 Oct; 18:5374-86.